Evidence map›Paper›PMID 34236607›Full record

ArticleHormones (Athens, Greece)2021

Comparison of the effects of medical and surgical treatments in giant prolactinoma: a single-center experience.

Soner Cander, Ozen Oz Gul, Eda Eylemer, Elif Gullulu Boz, Elif Gunes, Bahattin Hakyemez, Selcuk Yilmazlar, Canan Ersoy

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Hormones (Athens, Greece), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Long-term Follow-up of 84 Patients With Giant Prolactinomas-A Swedish Nationwide Study.The Journal of clinical endocrinology and metabolism · 2023
    Article
  5. Surgical Management of Giant Prolactinomas: A Descriptive Study.International journal of endocrinology · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Soner CanderEndocrinology and Metabolism, Bursa Uludag University Medical School, Bursa, Turkey. drcander@gmail.com.ORCID http://orcid.org/0000-0001-6303-7896
Ozen Oz GulEndocrinology and Metabolism, Bursa Uludag University Medical School, Bursa, Turkey.
Eda EylemerInternal Medicine, Bursa Uludag University Medical School, Bursa, Turkey.
Elif Gullulu BozInternal Medicine, Bursa Uludag University Medical School, Bursa, Turkey.
Elif GunesEndocrinology and Metabolism, Bursa City Hospital, Bursa, Turkey.
Bahattin HakyemezBursa Uludag University Medical School, Neuroradiology, , Turkey.
Selcuk YilmazlarBursa Uludag University Medical School, Neurosurgery, , Turkey.
Canan ErsoyEndocrinology and Metabolism, Bursa Uludag University Medical School, Bursa, Turkey.
Bursa Uludağ Üni̇versi̇tesi̇ · TRBursa Technical University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGiant prolactinomas, which have extremely large sizes and high prolactin (PRL) values, are rarely seen. Although medical therapy is effective, surgical treatment is more frequently applied due to slightly lower response rates and compression symptoms. This study aimed to compare the medical and surgical treatment results in giant prolactinomas.

methodsThirty-nine patients who were followed up in our center for giant prolactinoma were included in the study, and the response rates of the patients were evaluated after the medical and surgical treatments. The treatment responses were compared in terms of tumor volume, PRL level, visual field, and pituitary function.

resultsThe outcomes of the 66 treatment periods (medical n = 42; surgical n = 24) in 39 patients (mean age, 47.2 years; men, 89.7%) were evaluated. The most common presentations were hypogonadism and visual defects. The mean longest tumor diameter at diagnosis was 52.2 ± 11.8 mm, and the median PRL levels were 5000 ng/mL. PRL level normalization was achieved in 69% with medical therapy, and a curative response was obtained in only two patients with surgery. Tumor volume reduction was 67% (no cure) in the medical and 75% (13% cure) in the surgical groups (p = 0.39). Improvement of visual field was 70.8% in the medical and 84.2% in the surgical group (p = 0.12).

conclusionIn our study, it was observed that medical therapy was effective and safe in patients with giant prolactinomas. The use of surgical treatment should be limited to prolactinomas with compression or post-resistance to medical treatment in serious cases.

Indexed as

Pituitary NeoplasmsProlactinomaFemaleFollow-Up StudiesHumansMaleMiddle AgedPituitary GlandProlactinTreatment OutcomeProlactinGiant prolactinomaHypopituitarismMedical treatmentPituitary adenomasProlactinTumor volumeVisual field defects

Identifiers

PMID34236607
OpenAlexW3178209886

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.